Pfizer Inc. reports results for the quarter ended September 30 - Earnings Summary

Pfizer

03/11/2026 14:31

Pfizer Inc. PFE.N reported quarterly adjusted earnings of 87 cents​​ per share for the quarter ended September 30, identical to the same quarter last year.  The mean expectation of nineteen analysts for the quarter was for earnings of 73 cents per share. Wall Street expected results to range from 56 cents to 83 cents per share.
Revenue fell 0.4% to $16.58 billion from a year ago; analysts expected $15.87 billion. 
Pfizer Inc.'s reported EPS for the quarter was 56 cents​.
The company reported quarterly net income of $3.24 billion.
Pfizer Inc. shares had risen by 7.5% this quarter and gained 23.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.6% in the last three months.​ 
In the last 30 days, nine analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 10 "strong buy" or "buy," 17 "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for Pfizer Inc. is $28.00, about 9.5% below its last closing price of $30.67
This summary was machine generated from LSEG data November 3 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
0.73
0.87
Beat
Jun. 30 2026 
0.68
0.77
Beat
Mar. 31 2026 
0.72
0.75
Beat
Dec. 31 2025 
0.57
0.66
Beat